TPP1 and lysosomal storage disease: CLN2 is a lysosomal storage disorder that results from dysfunctional lysosomal enzyme tripeptidyl peptidase-1 (TPP1), encoded by TPP1. A 2019 study used macrophage-derived EVs to deliver soluble TPP1 protein for the treatment of CLN2 [63].